



Greenstone – Recall of diphenoxylate/atropine

- On November 16, 2017, the [FDA announced](#) a consumer-level recall of some lots of Greenstone's [diphenoxylate/atropine](#) tablets because product from these lots has the potential to be super potent or sub potent.
- The recalled products were distributed nationwide to wholesalers/retailers from November 2016 through June 2017.

Product Description	NDC #	Lot # (Expiration Date)
Diphenoxylate/atropine 2.5 mg/0.025 mg tablets, 1000-count bottle	59762-1061-02	R97310 (10/31/21); R93358 (10/31/21); R93357 (10/31/21); R93356 (10/31/21)
Diphenoxylate/atropine 2.5 mg/0.025 mg tablets, 100-count bottle	59762-1061-01	S57834 (11/30/21); S57832 (11/30/21); S57831 (11/30/21); R93352 (10/31/21); R93351 (10/31/21); R93350 (10/31/21); R93349 (10/31/21); R93348 (10/31/21); R93347 (10/31/21); R83962 (10/31/21)

- Diphenoxylate/atropine tablets are indicated as adjunctive therapy in the management of diarrhea in patients ≥ 13 years of age.
- The use of the recalled product in patients with uncontrolled diarrhea due to chronic medical conditions may predispose the patient to toxicity from either the diphenoxylate or atropine components.
- The product label states that over dosage can be life-threatening and symptoms may include opioid and/or anticholinergic effects including respiratory depression, coma, delirium, lethargy, dryness of the skin and mucous membranes, mydriasis or miosis, flushing, hyperthermia, tachycardia, hypotonia, tachypnea, toxic encephalopathy, seizures, and incoherent speech.
- Respiratory depression has been reported up to 30 hours after ingestion and may recur despite an initial response to narcotic antagonists.
- The use of the impacted super potent product when used as labeled has a low probability of being associated with adverse events of limited severity such as lethargy, skin flush, and drowsiness. Serious adverse events such as coma and respiratory depression are improbable. If a patient was to receive a sub potent tablet, symptoms may not be controlled.
- To date, there have been no reports of adverse events related to this recall.
- Anyone with an existing inventory of the recalled products should stop use and distribution and quarantine immediately.

Continued . . .

- For recall assistance, contact Stericycle at **1-855-215-4982**. For any clinical questions regarding this recall, contact Pfizer at **1-800-438-1985**.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.